Identification of the Most Cost-effective Position of Vedolizumab Among the Available Biologic Drugs for the Treatment of Ulcerative Colitis. [electronic resource]
Producer: 20210414Description: 575-587 p. digitalISSN:- 1876-4479
- Adalimumab -- therapeutic use
- Adult
- Algorithms
- Antibodies, Monoclonal, Humanized -- administration & dosage
- Azathioprine -- therapeutic use
- Biological Products -- economics
- Colectomy
- Colitis, Ulcerative -- drug therapy
- Cost-Benefit Analysis -- statistics & numerical data
- Drug Therapy, Combination
- Gastrointestinal Agents -- administration & dosage
- Humans
- Immunosuppressive Agents -- therapeutic use
- Infliximab -- therapeutic use
- Male
- Markov Chains
- Models, Economic
- Quality-Adjusted Life Years
- Tumor Necrosis Factor-alpha -- antagonists & inhibitors
No physical items for this record
Publication Type: Journal Article
There are no comments on this title.
Log in to your account to post a comment.